We’re on a mission to unlock molecular machines by understanding and respecting their complexities. We’ll be working incredibly hard to discover their untapped potential because we believe they are the key to delivering the next generation of precision medicines. We are unapologetically scientific, and we know this will help us achieve our mission to get new medicines to people in need. We’ve removed the bureaucracy and believe having a teammate’s back is critical to our success. You see, MOMA isn’t your typical biotech company. We are drug discovery professionals, industry specialists and scientific experts. More importantly, we’re collectively unstoppable.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Founded date: 2020
Investors 1
Mentions in press and media 4
| Date | Title | Description |
| 12.05.2022 | Inside SoftBank’s side letter with Better CEO Vishal Garg | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. On Nov. 30, a single day before the digital mortgage company would lay off 900 staffers, Kevin Ry... |
| 15.04.2020 | Moma Therapeutics aims at molecular machines with $86M raise | Moma Therapeutics wants to crack a new type of drug target wide open. The company snagged $86 million from the likes of Third Rock Ventures to systematically go after molecular machines, a family of more than 400 enzymes that others have on... |
| 15.04.2020 | Moma Therapeutics aims at molecular machines with $86M raise | Moma Therapeutics wants to crack a new type of drug target wide open. The company snagged $86 million from the likes of Third Rock Ventures to systematically go after molecular machines, a family of more than 400 enzymes that others have on... |
| 15.04.2020 | The newest, $86M Third Rock startup chases the tiny biological machines inside of you | It took 23 years from the isolation of the gene for cystic fibrosis to the approval of the first drug to target it, and another 7 for a drug that could treat the vast majority of CF patients. Third Rock Venture’s latest start... |